Pathogenesis and novel treatment options for non-alcoholic steatohepatitis

doi:10.1016/S2468-1253(16)30011-5

Review

. 2016 Sep;1(1):56-67.

doi: 10.1016/S2468-1253(16)30011-5. Epub 2016 Aug 10.

Pathogenesis and novel treatment options for non-alcoholic steatohepatitis

Vincent Wai-Sun Wong¹, Shiv Chitturi², Grace Lai-Hung Wong³, Jun Yu³, Henry Lik-Yuen Chan³, Geoffrey C Farrell²

Affiliations

¹ Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China; State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China. Electronic address: wongv@cuhk.edu.hk.
² Liver Research Group, Australian National University Medical School at The Canberra Hospital, Woden, ACT, Australia.
³ Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China; State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China.

PMID: 28404113
DOI: 10.1016/S2468-1253(16)30011-5

Review

Pathogenesis and novel treatment options for non-alcoholic steatohepatitis

Vincent Wai-Sun Wong et al. Lancet Gastroenterol Hepatol. 2016 Sep.

. 2016 Sep;1(1):56-67.

doi: 10.1016/S2468-1253(16)30011-5. Epub 2016 Aug 10.

Authors

Vincent Wai-Sun Wong¹, Shiv Chitturi², Grace Lai-Hung Wong³, Jun Yu³, Henry Lik-Yuen Chan³, Geoffrey C Farrell²

Affiliations

¹ Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China; State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China. Electronic address: wongv@cuhk.edu.hk.
² Liver Research Group, Australian National University Medical School at The Canberra Hospital, Woden, ACT, Australia.
³ Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China; State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China.

PMID: 28404113
DOI: 10.1016/S2468-1253(16)30011-5

Abstract

Non-alcoholic fatty liver disease affects 20-40% of the population. Its active form, non-alcoholic steatohepatitis (NASH), is characterised by hepatocyte injury, liver inflammation, and progression of fibrosis, and has emerged as one of the most important causes of liver failure and hepatocellular carcinoma. Weight reduction of 10% by dietary restriction and regular exercise is sufficient to reverse NASH in most patients, but in practice this reduction is often not achieved. Available drugs such as vitamin E, pioglitazone, and pentoxifylline have borderline efficacy, but are limited by potential side-effects and toxicities, and do not improve liver fibrosis. However, basic and translational research has improved our understanding of the pathophysiology of NASH, thereby identifying several promising new treatment targets. Several drugs are in phase 2 and 3 development and could enter clinical practice in the near future. In this Review, we discuss the pathogenesis, treatment evaluation, existing therapies, and potential new treatments for NASH.

PubMed Disclaimer

Cited by

NME4 mediates metabolic reprogramming and promotes nonalcoholic fatty liver disease progression.
Xie S, Yuan L, Sui Y, Feng S, Li H, Li X. Xie S, et al. EMBO Rep. 2024 Jan;25(1):378-403. doi: 10.1038/s44319-023-00012-6. Epub 2023 Dec 14. EMBO Rep. 2024. PMID: 38177901 Free PMC article.
Emerging medical therapies for non-alcoholic fatty liver disease and for alcoholic hepatitis.
Wong VW, Singal AK. Wong VW, et al. Transl Gastroenterol Hepatol. 2019 Jul 19;4:53. doi: 10.21037/tgh.2019.06.06. eCollection 2019. Transl Gastroenterol Hepatol. 2019. PMID: 31463412 Free PMC article. Review.
ER-residential Nogo-B accelerates NAFLD-associated HCC mediated by metabolic reprogramming of oxLDL lipophagy.
Tian Y, Yang B, Qiu W, Hao Y, Zhang Z, Yang B, Li N, Cheng S, Lin Z, Rui YC, Cheung OKW, Yang W, Wu WKK, Cheung YS, Lai PBS, Luo J, Sung JJY, Chen R, Wang HY, Cheng ASL, Yang P. Tian Y, et al. Nat Commun. 2019 Jul 29;10(1):3391. doi: 10.1038/s41467-019-11274-x. Nat Commun. 2019. PMID: 31358770 Free PMC article.
Adlercreutzia equolifaciens Is an Anti-Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease.
Oñate FP, Chamignon C, Burz SD, Lapaque N, Monnoye M, Philippe C, Bredel M, Chêne L, Farin W, Paillarse JM, Boursier J, Ratziu V, Mousset PY, Doré J, Gérard P, Blottière HM. Oñate FP, et al. Int J Mol Sci. 2023 Jul 31;24(15):12232. doi: 10.3390/ijms241512232. Int J Mol Sci. 2023. PMID: 37569608 Free PMC article.
Large-scale identification of undiagnosed hepatic steatosis using natural language processing.
Schneider CV, Li T, Zhang D, Mezina AI, Rattan P, Huang H, Creasy KT, Scorletti E, Zandvakili I, Vujkovic M, Hehl L, Fiksel J, Park J, Wangensteen K, Risman M, Chang KM, Serper M, Carr RM, Schneider KM, Chen J, Rader DJ. Schneider CV, et al. EClinicalMedicine. 2023 Aug 9;62:102149. doi: 10.1016/j.eclinm.2023.102149. eCollection 2023 Aug. EClinicalMedicine. 2023. PMID: 37599905 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Substances

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Pathogenesis and novel treatment options for non-alcoholic steatohepatitis

Affiliations

Pathogenesis and novel treatment options for non-alcoholic steatohepatitis

Authors

Affiliations

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical